A Prospective Observational Study for Comparative Evaluation of Combined Ipratropium Bromide-Levosalbutamol versus Levosalbutamol Monotherapy in the Management of Obstructive Pulmonary Diseases

Research Article

Authors

  • Vijayraj Kumar Molleti PharmD Intern, Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India Author
  • Kranthi Kiran Koyyuru PharmD Intern, Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India Author
  • Annie Christine Nadipalli PharmD Intern, Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India Author
  • P Krishna Rajeswari Chowdary Nekkanti PharmD Intern, Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India Author
  • Dileep Varma Inampudi PharmD Intern, Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India Author

DOI:

https://doi.org/10.69613/jzdqk620

Keywords:

Obstructive pulmonary disease, Ipratropium bromide, Levosalbutamol, Peak expiratory flow rate, Quality of life

Abstract

This prospective observational study is conducted to evaluate the efficacy of combined ipratropium bromide-levosalbutamol therapy compared to levosalbutamol monotherapy in managing obstructive pulmonary diseases. The study was conducted at GSL General Hospital and Medical College, Rajamahendravaram, over six months from October 2023 to April 2024. Thirty-nine patients were enrolled, with 26 receiving combination therapy and 13 receiving monotherapy. Treatment outcomes were assessed using Peak Expiratory Flow Rate (PEFR), St George's Respiratory Questionnaire (SGRQ), and Cough Symptom Score (CSS). Initial PEFR values were ≤130 L/min for all patients. Post-treatment, both groups showed significant improvements in PEFR, with the combination therapy group showing a mean increase from 80.51 to 147.69 L/min. SGRQ scores improved significantly in both groups, with mean scores decreasing from 55.25 to 30.11. CSS evaluations demonstrated substantial improvements in both daytime and nighttime symptoms across both treatment groups. Statistical analysis using the Wilcoxon Matched Pairs test revealed significant within-group improvements for all parameters (p<0.0001). However, between-group comparisons showed no statistically significant differences in treatment outcomes. It can be concluded from this study that both combination therapy and monotherapy are equally effective in managing obstructive pulmonary diseases, suggesting that either treatment approach can be safely implemented based on individual patient needs.

Downloads

Download data is not yet available.

Downloads

Published

05-12-2024

How to Cite

A Prospective Observational Study for Comparative Evaluation of Combined Ipratropium Bromide-Levosalbutamol versus Levosalbutamol Monotherapy in the Management of Obstructive Pulmonary Diseases: Research Article. (2024). Journal of Pharma Insights and Research, 2(6), 215-222. https://doi.org/10.69613/jzdqk620